Information Provided By: 
Fly News Breaks for January 4, 2019
DELL, ROK, INFI, CBIO, AVEO
Jan 4, 2019 | 10:31 EDT
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aveo Pharmaceuticals (AVEO) initiated with an Outperform at Baird. 2. Catalyst Biosciences (CBIO) initiated with Outperform at Oppenheimer. 3. Infinity Pharmaceuticals (INFI) initiated with a Buy at B. Riley FBR. 4. Rockwell Automation (ROK) resumed with a Hold at Deutsche Bank. 5. Dell Technologies (DELL) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
News For AVEO;CBIO;INFI;ROK;DELL From the Last 2 Days
DELL
Apr 19, 2024 | 06:39 EDT
UBS analyst David Vogt raised the firm's price target on Dell Technologies to $141 from $113 and keeps a Buy rating on the shares. The firm cites shorter GPU lead times and the broadening out of AI server demand from the hyperscalers to Tier 2 Cloud and ultimately Enterprise customers for the price target increase. UBS expects nearly 50% AI server unit growth in calendar 2024.
DELL
Apr 18, 2024 | 21:58 EDT
UBS raised the firm's price target on Dell Technologies to $141 from $113 and keeps a Buy rating on the shares. The firm contends that global AI related servers should increase 48% and 21% in 2024 and 2025 respectively, directionally acting as a tailwind for Dell's Infrastructure Solution Group / Server business despite sluggish legacy enterprise demand, the analyst tells investors in a research note. UBS adds however that it reduces its FY25 Client Solutions Group segment revenue forecast lower by 3.4% due to a slower PC recovery.
